Q4 2024 Earnings Call Transcript February 28, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

Proficio Capital Partners LLC bought a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the ...

UBS analyst Dan Leonard lowered the firm’s price target on Fulgent Genetics (FLGT) to $20 from $27 and keeps a Neutral rating on the shares.

Discover the top 5 undervalued Health Care Providers & Services stocks for Wednesday, March 12 based on AAII’s Stock Grades.

StockNews.com upgraded shares of Fulgent Genetics (NASDAQ:FLGT – Free Report) from a sell rating to a hold rating in a research report released on Wednesday. Separately, Piper Sandler decreased their ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Fulgent Genetics (FLGT) to $16 from $22 following quarterly results.

Full Year 2024 Results Key Financial Results Revenue: US$283.5m (down 2.0% from ...

Fulgent Genetics ( NASDAQ:FLGT ) Full Year 2024 Results Key Financial Results Revenue: US$283.5m (down 2.0% from FY... EL MONTE, Calif., February 28, 2025--Fulgent Genetics, Inc. (NASDAQ ...

FULGENT GENETICS ($FLGT) posted quarterly earnings results on Friday, February 28th. The company reported earnings of $0.04 per share, beating estimates of -$0.13 by ...

Greetings and welcome to the Fulgent Genetics Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode. [Operator Instructions]. A question-and-answer session ...

Fulgent Genetics specializes in laboratory services and therapeutic development. Its laboratory division provides anatomic pathology and precision diagnostic testing through certified laboratories ...